Published online Aug 27, 2021. doi: 10.4240/wjgs.v13.i8.848
Peer-review started: April 13, 2021
First decision: June 23, 2021
Revised: June 28, 2021
Accepted: July 19, 2021
Article in press: July 19, 2021
Published online: August 27, 2021
Clinicians are not familiar with the sclerosing angiomatoid nodular transformation (SANT), which is gaining recognition as a benign splenic tumor.
We challenge that SANT is rare and whether critical imaging review could help avoid unnecessary splenectomy.
This study aimed to evaluate the incidence of SANT among splenic tumors and the decision-making process of SANT management.
Twenty hospitalized patients who underwent splenectomy in 2018 and 2019 in a tertiary university hospital were retrospectively reviewed. Discriminative features differentiating SANT from other non-SANT splenic tumors were descriptively analyzed.
Fourteen splenectomies were indicated for splenic tumors, including 3 SANTs (21%). Hypointensity on T2-weighted magnetic resonance imaging, spoke wheel enhancing pattern, and cold spot in positron emission tomography scan helped establish the diagnosis of SANT. Splenectomy need not be performed in patients with typical imaging features of SANT.
SANT is not rare. Splenectomy should not be routinely indicated as the only management option for SANT with typical imaging features.
Further studies are needed to confirm the diagnostic imaging features of SANT in the future.